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1. Introduction 
Facioscapulohumeral muscular dystrophy (FSHD or Dejerine–Landouzy muscular 
dystrophy, OMIM #158900) is the third most common hereditary myopathy, with 
prevalence of 1 in 20,000 (Padberg, 1982; Mostacciuolo et al., 2009). This disease is 
characterized by the progressive wasting of a highly selective set of muscle groups 
(Padberg, 1982) and it has been traditionally classified as an autosomal dominant trait (Lunt, 
1998; Padberg, 1992). FSHD genetic locus has been mapped on chromosome 4q35 by genetic 
linkage analysis (Wijmenga et al., 1990). Interestingly, this muscular dystrophy has not yet 
been related to a classical mutation within a protein-coding gene, but rather the disease has 
been associated with DNA rearrangements in a polymorphic genomic region consisting of 
an array of tandemly repeated 3.3 kb segments, named D4Z4 (Wijmenga et al., 1992b). D4Z4 
contains an ORF encoding a putative homeobox protein called “DUX4.” The existence of 
native transcripts of DUX4 from D4Z4 single repeats is still controversial (Gabriels et al., 
1999; Hewitt et al., 1994; Lyle et al., 1995), although recent data show evidences of the 
presence of the DUX4 transcript from the last D4Z4 unit in FSHD myoblasts (Lemmers et al., 
2010a). The number of D4Z4 repeats varies from 11 to 100 in the general population, 
whereas less than 11 repeats are usually present in sporadic and familial FSHD patients. A 
very low copy number of 4q35 D4Z4 repeats (1–3) often correlates with an earlier onset and 
more severe disease. However no FSHD-linked array has been found to have zero copies of 
the repeat unit (Tupler et al., 1996; van der Maarel et al., 2007) suggesting that the repeat 
itself plays a critical role in the disease. Alleles with 4-7 repeats are the most frequent in the 
FSHD population and are associated with the more common form of FSHD that usually 
presents in adulthood, whereas alleles with 8-10 repeats typically display milder disease 
phenotypes with reduced penetrance. Nearly identical and equally polymorphic D4Z4 
sequences reside on the subtelomere of chromosome 10q (Bakker et al., 1995; Deidda et al., 
1995). The proportion of individuals in the general population carrying 4q or 10q 
chromosome ends with repeat arrays entirely or partially transferred between both 
chromosomes, is considerable (van Deutekom et al., 1996b; Lemmers et al., 1998; van 
Overveld et al., 2000). Rearrangements between 4q and 10q subtelomeres occur in 20% of 
 
Neuromuscular Disorders 22
subjects and represent an additional complication to FSHD molecular diagnosis. However, 
only subjects with reduced number of D4Z4 repeats on chromosome 4, but not on 
chromosome 10, develop FSHD. Thus, molecular diagnosis of FSHD is, at this time, based 
on the analysis of the D4Z4 polymorphic alleles (Lunt, 1998; Tawil et al., 2010). Despite the 
identification of the genetic defect associated with FSHD, the pathologic effects of the 
reduction of D4Z4 elements remain largely unknown. The observation of the unique linkage 
of the disease with chromosome 4, led to the hypothesis that in cis DNA elements must be 
present on D4Z4 reduced alleles to explain disease onset. An element within D4Z4 has been 
shown to behave as a silencer that provides a binding site for a transcriptional repressing 
complex (Gabellini et al., 2002). These results suggest a model in which reduction of D4Z4 
leads to the inappropriate transcriptional derepression of proximal chromosome 4-specific 
genes. Indeed, closely located genes such as FSHD Region Gene 2 (FRG2), FSHD Region 
Gene 1 (FRG1), and Adenine Nucleotide Translocator (ANT1), with high myopathic 
potential, were observed to be transcriptionally upregulated in FSHD muscle (Gabellini et 
al., 2002). However, studies testing this model obtained conflicting results with some 
showing support (Gabellini et al., 2002; Rijkers et al., 2004; Klooster et al., 2009; Bodega et al., 
2009), and others not (Winokur et al., 2003b; Jang et al., 2003; Osborne et al., 2007; Masny et 
al., 2010). These discrepancies prevented a general consensus on the role of 4q35 genes 
upregulation in FSHD pathogenesis. Recently it has been proposed that FSHD arises from 
chromosomes bearing a short D4Z4 repeat array associated with a novel polyadenylation 
signal capable of stabilizing DUX4 mRNA from the normally transcriptionally inactive 
DUX4 gene. However, there is reason to believe that this model does not account for all 
FSHD cases. For example, several studies described FSHD patients carrying full-length 
D4Z4 alleles that are clinically indistinguishable from FSHD subjects carrying D4Z4 reduced 
alleles. Conversely, there is a high percent of normal individuals, unrelated to any FSHD 
patients, with reduced D4Z4 alleles (Scionti et al., 2012b). Most importantly it has been 
recently showed that the polymorphism adding the polyadenylation signal to DUX4 RNA, 
is common in the general population. Thus, just a portion of subjects carrying this molecular 
signature develops FSHD (Scionti et al., 2012b).  Consequently, the number of D4Z4 repeats 
at 4q35 by itself or in association with a specific haplotype, does not to fully explain FSHD 
development. The non linear correlation between the number of D4Z4 elements and FSHD 
expression raises the question whether or when FSHD can be considered a simple 
autosomal dominant mendelian disorder, or if a more complex picture should be considered 
in clinical practice. Indeed, recent findings suggest that epigenetic modification at the 
disease locus, such as DNA methylation (de Greef et al., 2008), histone modifications (Zeng 
et al., 2009) or chromosomal architecture (Petrov et al., 2006) can be altered in FSHD 
patients, adding further levels of complexity. Undeniably, the incomplete knowledge of 
molecular mechanism(s) leading to FSHD onset has hampered the possibility of developing 
effective therapeutic strategies. This chapter aims to discuss the recent advances in our 
understanding of FSHD pathology viewed against its clinical heterogeneity, considering all 
the factors that can contribute to the complexity of this elusive disease. 
2. FSHD Clinical features: Role of D4Z4 repeats reduction 
2.1 Clinical features 
Facioscapulohumeral muscular dystrophy is considered an autosomal dominant myopathy 
characterized by progressive atrophy and weakness of a highly selective set of muscle 
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groups (Padberg, 1982). The onset of the disease is in the second/third decade of life and 
usually involves weakness of facial mimic muscles. The clinical presentation is characterized 
by an initially restricted distribution of weakness starting with asymptomatic facial weakness 
followed by scapular fixator, humeral, truncal, and lower extremity weakness. The onset of 
lower-extremity weakness is typically in the anterior leg compartment, presenting with 
footdrop. Extraocular and bulbar muscles are typically spared. Although facial weakness is 
perhaps the most recognizable aspect of FSHD, affected individuals from otherwise clinically 
typical families may have no or minimal facial weakness (Flanigan et al., 2004). Weak 
abdominal muscles result in a protuberant abdomen and contribute to the lumbar lordosis. 
Lower abdominal muscles are weaker than the upper abdominal muscles, causing a strikingly 
positive Beevor’s sign, a physical finding fairly specific for FSHD. In advanced cases, hip 
girdle may be as affected or more than shoulder girdle muscles, making difficult the clinical 
distinction between FSHD and limb-girdle muscular dystrophy. A notable distinctive feature 
of FSHD is that muscle weakness displays an asymmetric distribution, which does not 
correlate with the handedness of the individual (Brouwer et al., 1992). The chronology of 
disease progression is unpredictable; for example, long periods of stability can be followed by 
sudden and dramatic worsening. In addition, there is a wide variability in the spectrum of 
disease among patients, ranging from subjects with very mild muscle weakness, who are 
almost unaware of being affected, to those who are wheelchair-dependent. This variability in 
disease penetrance was exemplified by a set of monozygotic male twins who carried the same 
genetic mutation but were affected by FSHD to a dramatically different extent (Tupler et al., 
1998). Electromyography and histological analysis reveal non-specific myopathic changes 
associated, in some cases, with neurologic  aspects. The creatine kinase (CK) level can be 
moderately increased or normal. Thus, diagnosis of FSHD is mainly based on the clinical 
phenotype in combination with a molecular test (Lunt et al 1995; Lunt, 1998). Ancillary 
features such as sensorineural deafness or retinal vasculopathy have been also reported in 
FSHD patients, but they are not to be considered decisive criteria for FSHD diagnosis 
(Fitzsimmons et al., 1987; Padberg et al., 1995; Trevisan et al., 2008). 
2.2 Molecular diagnosis 
The FSHD genetic defect does not reside in mutation of any protein-coding gene. Instead 
FSHD has been causally associated with reduction of the number of 3.3 kb DNA elements at 
the subtelomeric region of chromosome 4q. When digested with the restriction enzyme 
EcoRI the FSHD allele originates a fragment of 35 kb in size or shorter that can be detected 
by Southern analysis using the probe p13E-11 (Wijmenga et al., 1992b). The polymorphic 
genomic region, identified by probe p13E-11, consists of an array of tandem repeat 3.3-kb 
segments (hereafter referred to as D4Z4 repeats), such that the variation in the size of EcoRI 
fragments is due to variability in the number of D4Z4 repeats (van Deutekom et al., 1993) 
(Figure 1). Normal subjects carry p13E−11 EcoRI alleles longer than 50 kb (>10 D4Z4 units) 
originating from chromosome 4 whereas alleles of 35 kb or shorter (≤ 8 D4Z4 units) are 
present in the majority of either de novo or familial FSHD patients (Lunt, 1998). De novo 
reduced allele transmitted by an affected parent to the offspring co-segregate with the 
disorder (Griggs et al., 1993). New mutations account for a surprisingly high percentage of 
FSHD patients (10%−33%) (Padberg et al., 1995; Zatz et al., 1995). This high incidence can be 
partly explained by the presence of parental mosaicism for 4q short alleles that has been 
reported in 19% of de novo cases (Upadhyaya et al.; 1995, Köhler et al.; 1996, Lemmers et al., 
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2004). The presence of somatic mosaicism for a rearrangement of D4Z4 was found in as 
much as 3% of the general population (van der Maarel et al., 2000), suggesting that the D4Z4 
repeat is highly recombinogenic.   
A complication of molecular testing by Southern analysis is represented by the presence of a 
polymorphic region recognized by probe p13E-11 at the subtelomeric region of chromosome 
10q, which shares numerous homologies with the 4q subtelomere (Bakker et al., 1995; Deidda 
et al., 1996). The repeat element at 10q is 98% identical to D4Z4 at 4q, and the size of 10q EcoRI 
alleles varies between 11 and 300 kb (1-100 D4Z4 units). Moreover, 10% of these alleles are 
shorter than 35 kb (8 D4Z4 units) (Bakker et al., 1996; Bakker et al., 1995), overlapping the 4q 
alleles. Clearly these overlapping features can interfere with the molecular diagnosis of FSHD. 
Nevertheless the presence of a BlnI restriction site within the 3.3 kb element associated with 
chromosome 10q allows the discrimination between 4q and 10q alleles (Deidda et al., 1996). As 
a result, Southern blot hybridization of EcoRI and EcoRI/BlnI digested genomic DNA is used 
for the molecular diagnosis of FSHD (Lunt, 1998) (Figure 1).   
 
Fig. 1. Schematic representation of Polymorphisms at the 4q and 10q subtelomeres. 
Schematic representation of the method used to calculate D4Z4 repeat numbers from EcoRI-
fragment sizes. Seven and eight D4Z4 repeats (31-36 kb EcoRI fragment size) were defined to 
be the upper diagnostic range for FSHD. D4Z4 repeat units on chromosomes 4 and 10 can be 
distinguished because all repeats on 10q contain BlnI restriction sites (B), while all D4Z4 
repeats on 4q contain XapI restriction sites (X). 
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Through years, additional findings have emerged that need to be considered in the 
molecular diagnosis of FSHD. First, translocated 4-type repeats residing on chromosome 10q 
as well as translocated 10-type repeats residing on chromosome 4q are found in 10% of the 
population (van Deutekom et al., 1996b; van Overveld et al., 2000; Matsumura et al., 2002;). 
Therefore, FSHD-sized D4Z4 alleles may be attributed incorrectly to chromosome 10 and 
viceversa. Second, deletions at 4q encompassing the genomic sequence recognized by probe 
p13E-11 have been detected in FSHD cases. Thus D4Z4 short arrays might not be detected 
by using the standard diagnostic procedure. The frequency of such extended deletions has 
been estimated around 3% (Lemmers et al., 2003) and represents a possible caveat of FSHD 
molecular diagnosis. Third, 5-10% of subjects showing FSHD clinical features do not carry 
D4Z4 reduced alleles. Possible explanations for such anomalous cases include a different 
mechanism at 4q35, such as D4Z4 hypomethylation (De Greef et al, 2009) or the presence of 
other mutations not linked to the FSHD locus at 4q35. At present, no FSHD families linked 
to other chromosomal loci have been described. Figure 2 summarizes the diagnostic flow 
chart that should be used to study the 4q35 region in FSHD patients. 
 
Fig. 2. Schematic representation of FSHD diagnostic approach at 4q35 locus. 
Abbreviations: Ch.DNA: chromosomal DNA embedded in plugs; Gen.DNA: genomic DNA 
in solution; PFGE: Pulse Field Gel Electrophoresis; LGE: Linear Gel Electrophoresis;  
E: restriction enzyme EcoRI; B: restriction enzyme BlnI; X: restriction enzyme XapI;  
N: restriction enzyme NotI; H: restriction enzyme HindIII. 
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2.3 FSHD clinical ascertainment and molecular diagnosis: Necessity of standardized 
clinical examination 
As said before, genomic studies conducted on groups of FSHD patients and families 
revealed the numerous difficulties that can be encountered in the molecular characterization 
of the 4q35 locus. Through years, the complexity of molecular diagnosis has been paralleled 
by the emerging complexity of FSHD clinical ascertainment. At present, criteria established 
in 1991, before the advent of molecular diagnosis (Padberg et al., 1991), and in 1998, 
following the ENMC workshop on FSHD (Lunt 1998), need probably to be reconsidered in 
light of the most recent observations.  
2.3.1 Penetrance 
Non-penetrance in FSHD was estimated to be less than 2% after the age of 50 years and 
more likely with allele sizes larger than 30 kb (Tawil et al., 1996). However, asymptomatic 
gene carriers seem to be more prominent in some families, and non-penetrance has even 
been found in carriers of 25 kb D4Z4 alleles (Ricci et al., 1999). In his work, Ricci et al. 
detected D4Z4 reduced alleles in several unaffected family members, named non-
penetrant carriers, who are capable of transmitting the disease to their offspring. In 
addition reduced penetrance for D4Z4 reduced alleles was described in families in which 
patients heterozygous for FSHD alleles on both 4q chromosomes were present 
(Wohlgemuth et al., 2003; Tonini et al., 2004). Gender differences have been also described 
in FSHD, with males apparently more affected than females (Tonini et al., 2004). 
Nowadays correlation between penetrance of FSHD, length of the repeat array, age and 
sex is unsettled. Thus, the risk of developing the disease in correlation with D4Z4 allele 
sizes cannot be estimated and no prognostic tools are available. In addition several clinical 
reports describe patients displaying clinical and genetic features of FSHD associated with 
other documented muscle disorders including mitochondrial diseases (Chuenkongkaew 
et al., 2005; Filosto et al., 2008), glycogenosis (Nadaj-Pakleza et al., 2009), 
dystrophinopathies (Rudnik-Schoneborn et al., 2008). In all these cases the presence of the 
FSHD molecular defect seems to aggravate the clinical phenotype.  Finally, phenotypic 
features of FSHD can be found in other myopathies (Oya et al., 2001; Saenz et al., 2005) as 
well as atypical phenotypes can be displayed by subjects carrying the FSHD molecular 
defect (Figueroa and Chapin, 2010; Tsuji et al., 2009; Zouvelou et al., 2009). All together 
these observations suggest that the variable penetrance observed in the FSHD population 
may be the result of the interaction of several factors. Indeed the presence of low-
penetrant alleles suggests that susceptibility for FSHD is not only determined by the 
intrinsic properties of the diseased allele but also by additional factors that can be genetic, 
epigenetic and/or environmental factors. Identification of factors influencing FSHD 
clinical outcome remains one of the major challenges of FSHD research.  
2.3.2 Severity of the disease and repeats number: Does a linear correlation exist? 
An inverse relationship has been established between the D4Z4 repeat size and the severity 
and progression of the disease (Lunt et al., 1995; Ricci et al., 1999; Tawil et al., 1996; Zatz et 
al., 1998). In general, individuals with ≥11 repeats are healthy; in contrast, 1-3 D4Z4 repeats 
is associated with a severe form of disease that presents in childhood, 4-7 repeats with the 
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most common form of FSHD, and 8-10 repeats with a milder disease and reduced 
penetrance. Nevertheless great variability of clinical expression has been described among 
FSHD patients even within the same family. Interestingly it has been suggested that patients 
harboring D4Z4 alleles of ≥35 kb (≥ 8 repeats) were less likely to present the classic FSHD 
phenotype as compared with patients with alleles of <35 kb (<8 repeats) (Felice and 
Whitaker, 2005). Several clinical reports described myopathic patients, carrying alleles of 38 
kb (9 repeats) or larger, showing typical and atypical FSHD phenotypes (Vitelli et al., 1999; 
Felice et al., 2000; Felice and Moore, 2001; Butz et al., 2003; Krasnianski et al., 2003).  
However D4Z4 repeat arrays of size between 38-45 kb (9-11 repeats) were encountered in 
3% of 200 control subjects in a Dutch study (van Overveld et al., 2000). These findings seems 
to indicate that in a substantial proportion of 38 to 45 kb-sized repeat arrays penetrance may 
be close to zero, but in some families 38−45 kb alleles are associated with myopathy (Butz et 
al., 2003). Remarkably D4Z4 repeat array of size between 21-34 kb (4-8 repeats) were found 
in 3% of 801 Italian and Brazilian samples of normal individuals unrelated to any FSHD 
patients, indicating that in this size-range, additional factors influence the disease 
expression (Scionti et al., 2012b). In conclusion the high variability in clinical expression 
makes difficult to establish a prognostic correlation between the number of the D4Z4 repeats 
and the severity of the disease. There is the necessity of clinical and molecular studies on 
large cohorts of FSHD patients and families to obtain significant information on FSHD 
development and generate useful prognostic information. 
2.3.3 A standardized clinical evaluation tool: FSHD score 
Based on the need of gaining statistically significant observations through large cohorts 
studies, a standardized clinical evaluation tool for patients with FSHD was created. The 
clinical protocol examines muscle groups specifically affected in FSHD. The test uses 
functional criteria, which allow expression of clinical severity in quantitative terms 
(Lamperti et al., 2010). The clinical examination results in an evaluation scale, which is 
divided into six independent sections that assess the strength and the functionality of (I) 
facial muscles (scored from 0 to 2); (II) scapular girdle muscles (scored from 0 to 3); (III) 
upper limb muscles (scored from 0 to 2); (IV) distal leg muscles (scored from 0 to 2); (V) 
pelvic girdle muscles (scored from 0 to 5); and (VI) abdominal muscles (scored from 0 to 1). 
The evaluation scale allows the functional quantification of muscle weakness in FSHD 
patients. This examination protocol, which is associated with a questionnaire that collects 
information on the clinical history of the subject, generates a disability score resulting from 
the sum of six independent scores of separately evaluated muscle regions, including the 
facial and abdominal muscles, which are specifically affected by FSHD. The total score can 
range from 0, when no signs of muscle weakness are present, to 15, when all muscle groups 
tested are severely impaired. The protocol represents a robust evaluation procedure for 
FSHD patients that can be performed easily in the medical office and is not influenced by 
the tester. The robustness of the clinical evaluation protocol provides a tool that can 
therefore be used by different neurologists in large cooperative clinical studies and allows 
translating what is called clinical impression of the progressive involvement of specific 
muscle groups into a number (Lamperti et al., 2010) (The FSHD clinical form and the FSHD 
evaluation scale form, as well as a visual guide to clinical assessment, are available online at 
www.fshd.it). 
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Use of the FSHD score can support studies for defining the natural history of the disease 
throughout time. Importantly, definition of the clinical involvement of specific muscle 
groups by a number permits identification and characterization of atypical cases and 
support the definition of clinical subcategories among FSHD patients.  
By assessing the correlation between clinical severity, results of molecular analysis, and 
anamnestic records, the FSHD score can provide useful information for defining FSHD 
nosology. 
3. Genomic characteristic of the 4q35 region: D4Z4 and role of specific 
polymorphisms 
Since the discovery of the FSHD molecular defect (Wijmenga et al 1992b), many studies 
suggested the possibility that reduction of D4Z4 repeat units on chromosome 4 alone is not 
sufficient to FSHD development (Weiffenbach et al 1993; van Overveld et al., 2000; Lemmers 
et al., 2002, Lemmers et al., 2007). Thus, a detailed genomic characterization of the 4q35 
region led to the identification of polymorphic regions flanking the D4Z4 repeat array which 
could contribute to FSHD onset. 
3.1 Genetic variability and haplotypes 
D4Z4 is part of a family of 3.3-kb repeats (D4Z4) are dispersed throughout the human 
genome and are generally found associated with regions of heterochromatin (Lyle et 
al.,1995). A homologue D4Z4 tandem array is present at the 10q telomere. This homology 
between the subtelomeric region of 10q and 4q is not confined to D4Z4 repeats but extends 
proximal 42 kb and distally to include the telomere (van Geel et al., 2002). However, despite 
the high level of sequence similarity (> 98% nucleotide identity) between the 10q and 4q 
subtelomeres, FSHD is associated only with the chromosome 4q (Bakker et al., 1995; Deidda 
et al., 1996). In the attempt of explaining the unique association between D4Z4 reduction of 
chromosome 4q and FSHD, a bi-allelic polymorphism was identified distal to the repeat 
array (van Geel et al., 2002).  Two distinct polymorphic regions, named 4qA and 4qB, were 
observed at the distal end of chromosome 4q. Within 4qA there is a polymorphic 8-kb 
region of 68bp satellite DNA immediately distal to the D4Z4, and adjacent to this is a 1-kb 
divergent (TTAGGG)n array. None of these repeats is present within the 4qB sequence. In 
4qB polymorphism, the last 3.3-kb repeat contains only the first 570 bp of a complete unit, 
whereas in 4qA the terminal repeat is a divergent 3.3-kb repeat named pLAM (van 
Deutekom et al., 1993). Sequence alignment and subsequent phylogenetic analysis of 
subtelomeric region of 10q showed a close relationship between 4qA sequences and 10q 
suggesting that the 4q subtelomere has been transferred onto chromosome 10q (van Geel et 
al., 2002). The distribution of these allelic variants is heterogeneous and depends on the 
studied population. Lemmers and colleagues (2004), analyzing 80 Dutch control individuals, 
have observed an almost equal frequencies of 4qA and 4qB alleles (42% and 58%, 
respectively), whereas in another study, conducted on 66 Italian control individuals, an 
overrepresentation of 4qA telomeres has been reported (68% for 4qA and 32% for 4qB) 
(Rossi et al., 2007). Proximal to the D4Z4 repeat array a simple sequence-length 
polymorphism (SSLP) has been described and those sequences are in a range between 157 
bp and 180 bp (Figure 3). 
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Fig. 3. The D4Z4 repeat array within the subtelomere of chromosomes 4q and 10q varies in size 
between 1 and 100 D4Z4 units (3.3–330 kb) and it is indicated with triangles. Elements that 
distinguish subjects include: 1. The chromosomal localization of the D4Z4 repeat, chromosome 
4q35 or 10q26. 2. The Simple Sequence Length Polymorphism (SSLP). It is a combination of 
five Variable Number Tandem Repeats, an 8 bp insertion/deletion, and two SNPs localized 3.5 
kb proximal to D4Z4 and vary in length between 157 and 182 bp. 3. Single nucleotide 
polymorphism AT(T/C)AAA (SNP) in the pLAM region. 4. A large sequence variation 
(termed 4qA or B) that is distal to D4Z4. In the 4qB variant the terminal 3.3-kb repeat contains 
only 570 bp of a complete repeat, whereas in the 4qA variant the terminal repeat is a divergent 
3.3-kb repeat named pLAM. 4q chromosomes which do not hybridize to probes for A and B 
are termed “null” and their sequences vary from case to case. 
A worldwide population (including African, European and Asian HAPMAP panels) 
analysis of 4q subtelomeric polymorphisms flanking the D4Z4 array revealed 17 distinct 
haplotypes on chromosome 4q (Lemmers et al., 2010b). On the basis of sequence similarities, 
all haplotypes were categorized in two groups: the major group 1 consists mainly of the 
haplotypes 4A159, 4A161 and 4B163, which are the most common in all three HAPMAP 
populations. The major group 2 contains other standard and nonstandard 4q haplotypes 
(4A166 and 4A168). Evolutionary studies showed that haplotypes 4A159 and 4A161 
represent the oldest human D4Z4 haplotypes. Similarly, the 4A168 haplotype is most 
probably the oldest haplotype that belongs to major group 2. It has been hypothesized that 
all other haplotypes originate from only four discrete sequence-transfer events during 
human evolution (Lemmers et al., 2010b).  
3.2 Permissive and non-permissive genetic background 
Analysis of 4qter polymorphisms of 80 unrelated Dutch patients with FSHD revealed that 
D4Z4-reduced alleles are associated with the 4qA variant (Lemmers et al., 2002). 
Subsequently, by studying three families in which two D4Z4-reduced alleles segregate, it 
has been proposed that 4qB chromosomes carrying short D4Z4 repeats do not cause FSHD, 
since only subjects carrying D4Z4-reduced alleles associated with the 4qA polymorphism 
had FSHD (Lemmers et al., 2004). The almost exclusive association between FSHD disease-
expression and the D4Z4-reduced allele of the 4qA type has been confirmed in a large 
cohort of 164 unrelated patients with FSHD from Turkey and the UK. Even though that 
study described FSHD patients lacking the 4qA/4qB end (Thomas et al., 2007). Subsequent 
studies led to the hypothesis that D4Z4 contraction on 4qA chromosome per se is not 
sufficient to cause disease. Analysis of SSLP proximal to the repeat array in 86 FSHD patients 
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and 222 healthy controls revealed a unique association of FSHD with the 161 allele and the 
4qA sequence. In particular the haplotype 4A166 associated with D4Z4-reduced alleles was 
detected in multiple unaffected relatives of two independent families and the 4B163 haplotype 
was associated with 17 FSHD-sized alleles carried in healthy subjects (Lemmers et al., 2007). 
On this basis it has been hypothesized that FSHD can develop only in a specific “permissive” 
chromosomal background represented by the haplotype 4A161. Following this hypothesis, 
proximal and distal sequences of 4A161 chromosome were compared to those of “non-
permissive” ones, such as 4B163 and 10A166. This approach led to the identification of a single 
nucleotide polymorphism (SNP, AT(T/C)AAA) in the adjacent pLAM sequence, immediately 
distal to D4Z4 array. In particular 4A161 and two other uncommon permissive variants, 4A159 
and 4A168 presented the ATTAAA variant, which has been interpreted as a polyadenylation 
signal able to stabilize the DUX4 transcript (Figure 4a).  
 
Fig. 4. Schematic representation of the current view of permissive and not-permissive 
haplotype. a. Permissive haplotypes b. Non-permissive haplotype. The ATTAAA variant 
creates a polyadenylation signal (PAS) that stabilizes the DUX4 transcript and has been 
postulated to be the critical factor causing FSHD. 
By contrast sequences associated with non-permissive chromosome 10A166 and 4B did not 
allow the expression of DUX4 (Lemmers et al., 2010a). Analysis of more than 300 unrelated 
FSHD patients and 5 families with one or more FSHD patients carrying D4Z4-reduced allele 
strongly supported the hypothesis that the last 4qA D4Z4 unit with the directly adjacent 
pLAM sequence including the ATTAAA is necessary to the FSHD development (Lemmers 
et al., 2010a). On this basis it has been proposed that FSHD arises through a toxic gain of 
function attributable to the stabilized distal DUX4 transcript (Lemmers et al., 2010a) (Figure 
4b). Despite the intriguing premise, the notion that FSHD is a fully-penetrant autosomal 
dominant disorder caused by the reduction of D4Z4 repeat number associated with 
4A161PAS haplotype is challenged by recently published data. First a study conducted on 
750 unrelated FSHD families from Italy revealed that the frequency of individuals carrying 
two D4Z4 reduced alleles (compound heterozygotes) is 2,7%, a frequency much higher than 
expected for a fully penetrant autosomal dominant disorder with prevalence of 1 in 20,000. 
Interestingly in these families with compound heterozygosity, 25% of relatives carrying 
D4Z4-reduced alleles and 4A161PAS are healthy (Scionti et al., 2012a). Second, 
characterization of 253 unrelated FSHD probands from the Italian National Registry for 
FSHD showed that only 127 of them (50.1%) carry D4Z4 alleles with 1-8 D4Z4 associated with 
4A161PAS, whereas the remaining FSHD probands carry different haplotypes or alleles with 
greater number of D4Z4 repeats (Scionti et al., 2012b). Third, molecular analysis of 801 normal 
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healthy subjects from Italy and Brazil showed that that 3% of individuals from the general 
population carry alleles with reduced number (4-8) of D4Z4 repeats on chromosome 4q and 
one third of these alleles occurs in combination with the 4A161PAS haplotype (Scionti et al., 
2012b) All these findings challenge the hypothesis that 4APAS structure is necessary and 
sufficient for the development of FSHD. This discovery is not incompatible with evidence 
implicating DUX4 or other factors as important mediators of disease. Nonetheless, it does 
demonstrate that FSHD pathogenesis is more complex than currently thought.  
4. One disease (too) many theories  
After the genetic correlation between D4Z4 and FSHD the most difficult task has been to 
explain the role of D4Z4 in disease development. D4Z4 can directly cause FSHD through 
DUX4 expression; on the other end D4Z4 reduction might indirectly cause FSHD by exerting 
long distance effects. None of the proposed models entirely explain the mechanism leading to 
disease. In this regard the scientific community does not express undisputed consensus.  
 
Fig. 5. Models for the molecular basis of FSHD. A. Healthy individuals carry 11–150 units 
of D4Z4, whereas FSHD patients have less than 11 repeats. B. DIRECT MECHANISM:  
reduction of D4Z4 repeat array leads to the synthesis of DUX4 transcript, which is normally 
not transcribed, through changes in D4Z4 heterochromatin and/or stabilization of DUX4 
mRNA. C. INDIRECT MECHANISM: the reduction of D4Z4 repeats leads to modifications 
of the spatial and structural organization of chromatin generating changes of transcriptional 
control over the expression of candidate genes localized in cis or in trans. 
A
B C 
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In examining all the models that have been proposed it is important to remember essential 
points: 
 80-85% of FSHD patients carry a reduction in D4Z4 whereas loss of the whole array is 
not associated with FSHD;  
 15-20% of FSHD patients have a normal number of repeats;  
 No specific 4q haplotype is associated with FSHD; 
 25% of relatives carrying D4Z4 alleles who are old than 56 years do not have FSHD; 
 Healthy individuals bearing allele with reduced number of repeats (4-8 units) are 
present in 3% of the healthy population; 
 Repeat reduction in the highly homologous D4Z4 copy on chromosome 10 is not 
associated with the FSHD; 
 Penetrance of the FSHD is not complete and its severity does not clearly correlate with 
number of repeats; 
Notably in all proposed models, epigenetic changes such as methylation or histone 
modifications are used as an additional level of complexity that might help interpreting the 
complex correlation between genotype and phenotype in FSHD. In this paragraph we will 
shortly describe the main mechanisms that have been proposed. In the following 
paragraphs all the factors that have been considered important for the disease onset will be 
explained in detail.  
4.1 Direct mechanism: DUX4 
The most recent model proposed to explain FSHD pathogenesis is based on the idea that the 
most distal copy of the DUX4 gene, whose open reading frame is present in each D4Z4 
repeat, is transcribed and the expression of this gene has a direct role in FSHD 
pathophysiology. At first it has been proposed that partial reduction of the D4Z4 repeat 
array results in destabilization of the D4Z4 heterochromatin and in the inappropriate 
upregulation of DUX4 gene (Gabriels et al., 1999; Hewitt et al., 1994). However this 
hypothesis has never been proven. This model has been consequently modified introducing 
the concept of a “permissive” chromosomal background namely a single nucleotide 
polymorphism in the pLAM sequence that provides a polyadenylation signal (PAS) for the 
DUX4 transcript. This should stabilize the DUX4 transcript from the most distal D4Z4 unit 
on 4q chromosomes resulting in disease through a toxic gain-of-function mechanism 
(Lemmers et al., 2010b) (Figure 5A). 
4.2 Indirect mechanism: Iindirect overexpression of candidate genes 
All the other models proposed to explain the role of D4Z4-reduced alleles in FSHD 
pathogenesis, predict that D4Z4 reduction is able to generate a modification in the spatial 
and structural organization of chromatin at 4q35. As a consequence loss of transcriptional 
control over the expression of candidate genes, localized in cis or in trans, is generated 
(Figure 5B). 
Cis-spreading model:  4q35 genes derepression 
D4Z4 contains heterochromatic DNA elements. It was thus reasoned that D4Z4 and 
surrounding sequences would be strongly packed as heterochromatin. Based on this idea, it 
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was hypothesized that loss of D4Z4 repeat would produce a local chromatin relaxation (i.e., 
loss of heterochromatinization) and, consequently, the transcriptional upregulation of genes 
nearby D4Z4, possibly in a distance-related manner  (Hewitt et al., 1994; Winokur et al., 1994). 
The identification of a repressor complex that binds to a specific 27 bp DNA element within 
D4Z4 (Gabellini et al., 2002) supports the cis-spreading model. Consistently, three 4qter 
genes (FRG2, FRG1, and ANT1) were found upregulated in muscle of FSHD patients 
(Gabellini et al., 2002). 
Cis-looping model: 4q35 genes derepression  
According to this model, D4Z4 is able to interact with target gene(s) by long-distance loops 
only when the D4Z4 contraction impairs the formation of normal D4Z4 intra-array loops. 
The hypothesis that normal-sized D4Z4 repeats form intra-array loops is supported by the 
size distribution of D4Z4 repeats which is multimodal, with equidistant peaks 65 kb apart 
(van Overveld et al., 2000).  
Insulator model 
D4Z4 is localized between the distal heterochromatic telomeric sequences and the 
euchromatic sequences more upstream. It has thus been proposed that it might act as an 
insulator (van Deutekom, 1996a). Reduction of the repeat arrays would impair the 
separation between domains, and, consequently, the spreading of heterochromatic would 
silence proximal genes in cis. This model is supported by the finding that D4Z4 itself acts as 
an insulator, which interferes with enhancer–promoter communication and protects from 
position effect (Ottaviani et al., 2009). Results obtained with different experimental 
approaches demonstrated that both, the transcriptional factor CTCF (CCCTC-Binding 
factor), and the A-type intermediate filament Lamins binding, are necessary for D4Z4 
insulator function. In this model, FSHD contracted D4Z4 array associates with CTCF and A-
type Lamins at the nuclear periphery resulting in both cis and trans insulation of gene(s) 
physiologically interacting with the 4q35 terminal sequences (Ottaviani et al., 2010). This 
may lead to the miss regulation of these genes and to the FSHD phenotype. 
Cis model: Nuclear localization 
The FSHD genomic region at 4q35.2 is consistently and specifically localized at the nuclear 
envelope (Petrov et al., 2006; Ottaviani et al., 2009) in proliferating myoblasts, fibroblasts, 
lymphoblasts, and differentiated myotubes. Interestingly it is not the D4Z4 repeat itself that 
mediates interaction with the nuclear envelope but a  chromosome 4 genomic regions just 
proximal to the D4Z4 repeat (D4S139) (Masny et al., 2004; Ottaviani et al., 2009). Since FSHD 
region is localized to the nuclear periphery, an alternative model for FSHD pathogenesis has 
been proposed. In this model improper interaction with transcription factors or chromatin 
modifiers at the nuclear envelope could induce aberrant expression of genes localized in cis 
or in trans. However a differential localization of normal or FSHD alleles to the nuclear 
periphery has not been observed (Masny et al., 2004).  
Trans-effect model: Genome wide effect 
It has been also postulated that reduction of D4Z4 might have a more genome-wide effects, 
affecting other pathways, such the slow-to-fast fiber differentiation pathway (Celegato et al., 
2006) and the response to oxidative stress and myogenic differentiation pathway (Winokur 
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et al., 2003b). Because D4Z4 can be regarded as a docking platform for protein factors, loss 
of repeats may generate a local imbalance in the availability of D4Z4 proteins in the cell, 
and/or lead to new interaction with different proteins at the disease allele.  
5. Direct role of D4Z4: The double homeobox gene 4 (DUX4) 
The D4Z4 unit has been completely sequenced (Hewitt et al., 1994; Winokur et al., 1994 Lee 
et al., 1995). Each D4Z4 repeat unit contains an ORF with a double homeobox putatively 
encoding the DUX4 protein. DUX4 belongs to a family of highly homologous genes 
scattered throughout the genome. One almost identical copy, named DUX4c, is located 42 
kb proximal to the repeat array. Based on the presence of the molecular signature 4A-PAS, 
which should allow the stabilization of the mRNA from the distal copy of the DUX4 gene; it 
has been proposed that FSHD arises through a toxic gain-of-function mechanism 
attributable to the pathological expression of DUX4 mRNA (Lemmers et al., 2010a).  More 
detailed analysis of DUX4 expression shows that the DUX4 pre-mRNA can be alternatively 
spliced and apparently, the FSHD muscle expresses a different splice form of DUX4 mRNA 
compared to control muscle (Snider et al., 2010). It is important to note that DUX4 is a rare 
transcript and the amount of DUX4 has been estimated in one copy per cell. To explain how 
such low expression level of DUX4 can cause FSHD, it has been proposed that in FSHD 
muscle the DUX4 protein may exert its toxic effect in a small subset of nuclei, which express 
a relatively abundant amount of DUX4 transcript. The possible toxic effect of DUX4 has 
been inferred on the basis of in vitro and in vivo studies (Kowaljow et al., 2007; Bosnakovski 
et al., 2008; Wallace et al., 2011) in which DUX4 was expressed at very high levels. Thus in 
order to explain FSHD pathogenesis, it is difficult to reconcile those experimental 
observations with the very limited amount of DUX4 detected in human muscle cells.  
6. 4q35 genes in FSHD phatogenesis: Role of genes overexpression 
Although the exact molecular mechanism responsible for FSHD is unknown, it is a common 
agreement that reduction of D4Z4 elements might cause up-regulation of gene(s) in cis. A 
few genes have been considered as good candidates for FSHD based on their localization 
and/or function. 
This section will critically discuss function and potential role of 4q35 candidate genes in 
FSHD development. 
6.1 FSHD region gene 2 (FRG2)  
FSHD Region Gene 2 (FRG2) was originally identified by in silico gene prediction (Van Geel 
et al., 1999) as a region of 3 kb 37 kb proximal to the D4Z4 repeat array. Predicted exons are 
preceded by a putative muscle specific promoter. FRG2 gene is composed of four exons and 
encodes an mRNA of 2084 bp with two alternative polyadenylation sites. The FRG2 ORF 
encodes a putative protein of 278 amino acids. The FRG2 protein does not show significant 
homology to known proteins (Rijkers et al., 2004). Alternative splicing creates an additional 
alanine codon (Rijkers et al., 2004). Even though FRG2 has been shown to be nuclear, 
(Rijkers et al., 2004) its sequence contains not only two potential nuclear localization signals 
(NLS) but also a peroxisomal targeting signal (PTS1) at the carboxyterminal end of the 
protein (Swinkels et al., 1992). Copies of FRG2 are dispersed throughout the genome, 
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prevalently located in subtelomeric or pericentromeric regions (Winokur et al., 1994; van 
Geel et al., 1999; van Geel et al., 2002). However, only the FRG2 copies on chromosomes 4 
and 10 show a 98% identity, differing for just five nucleotide mismatches in the ORF (Rijkers 
et al., 2004). Experiments demonstrated that the FRG2 promoter is sensitive to the presence 
of D4Z4 repeat units making FRG2 an interesting candidate gene for FSHD pathophysiology 
(Rijkers et al., 2004). Indeed it has been shown that overexpression of FRG2 is obtained by 
suppressing the activity of the D4Z4 recognition complex (DRC) (Gabellini et al., 2002). 
Moreover data suggests that in muscle biopsies from FSHD patients, FRG2 overexpression 
inversely correlates with D4Z4 repeat number (Gabellini et al., 2002). However the 
overexpression of FRG2 in FSHD is still controversial. If there is a general agreement that 
mRNA is virtually absent in most of human tissue, there is no consensus regarding the 
expression of FRG2 in FSHD patients’ samples. FRG2 overexpression was reported in 
differentiating, but not proliferating myoblasts of FSHD patients (Rijkers et al., 2004). The 
overexpression of FRG2 in FSHD myotubes has not been fully confirmed in other works 
(Arashiro et al., 2009; Cheli et al., 2011; Masny et al., 2010; Osborne et al., 2007). The different 
outcomes of expression studies may be explained by the intrinsic difficulties in detecting 
FRG2 mRNA due to its low expression level and by the presence in the genome of multiple 
copies of FRG2. Moreover FRG2 is not represented in the gene arrays currently used for 
RNA expression studies.  Whether FRG2 is involved in FSHD pathogenesis still remains in 
discussion. Indeed muscle-specific overexpression of FRG2 in mice does not result in an 
aberrant phenotype (Figure 6A) (Gabellini et al., 2006), and FSHD patient with proximal 
deletion encompassing FRG2 have been found (Lemmers et al., 2003). Nevertheless it is 
worth mentioning that FRG2 appears late in the evolution together with D4Z4 repeats and it 
is not present in the mice genome making the mice model for FRG2 overexpression not 
conclusive. The function of this protein is still unknown. 
6.2 FSHD region gene 1 (FRG1) 
In the human genome FRG1 gene is located 125 kb centromeric to D4Z4 array on 
chromosome 4. As for many other genes from the 4q subtelomeric region, several copies of 
FRG1 are present in the human genome (van Deutekom et al., 1996c). The FRG1 copy on 
chromosome 4 encodes a 258-amino acid protein. Although the FRG1 protein does not share 
significant overall homology to any known protein, it contains two nuclear localization 
signals in the N-terminal region (NLSs, aa 22-25 and 29-32), a bipartite NLS in the C-
terminal region (aa 253-261) and a single fascin-like domain (aa 58-176), indicative of an 
actin-binding protein (Figure 6B), one potential RNA-binding domain (22-35 aa) 
homologous to several RNA-binding proteins (RBPs). FRG1 protein is highly conserved 
among invertebrates and vertebrates: human FRG1 shares 42% identity with C. elegans, 81% 
identity with Xenopus and 97% identity with mouse protein (Figure 6B). The high level of 
conservation throughout species suggests that FRG1 might have a very important function 
that is preserved during the evolution.  
Since its discovery, FSHD Region Gene 1 (FRG1) has been considered a candidate gene for 
FSHD (Van Deutekom et al., 1996c). Analysis of its expression level in muscle tissues 
obtained from FSHD patients and healthy subjects showed that FRG1 was abnormally up-
regulated in FSHD affected muscles. Significantly, in lymphocytes from FSHD patients, its 
expression was equivalent to that observed in normal tissue, indicating that this over-
expression in FSHD is muscle-specific (Gabellini et al., 2002). Consistent with this evidence, 
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Fig. 6. FSHD Region Gene 1 (FRG1). A. WT and FRG1, FRG2 and ANT1 transgenic mice. 
Only FRG1 transgenic mice develop a muscular dystrophy with features of the human 
disease. B. FRG1 protein domains C. Alignament of FRG1 homologs: human FRG1 shares 
42% identity with C. elegans, 81% identity with Xenopus and 97% identity with mouse. 
transgenic mice over-expressing FRG1 develop a muscular dystrophy with features of the 
human disease (Figure 6A). Importantly the myopathic features of these mice are corrected 
by the use of RNA interference to target and reduce FRG1 level in the affected muscles. 
Interestingly, the same result was obtained by two groups using two different experimental 
approaches (Wallace et al., 2011; Bortolanza et al., 2011). Furthermore, in muscles of FRG1 
transgenic mice and FSHD patients, specific pre-mRNAs undergo aberrant alternative 
splicing. Collectively, these results suggest that FSHD might results from inappropriate 
over-expression of FRG1 in skeletal muscle, which leads to abnormal alternative splicing of 
specific pre-mRNAs (Gabellini et al., 2006).  
Recent studies show the crucial role of FRG1 in maintaining proper muscle structure and 
function (Hanel et al., 2011; Hanel et al., 2009; Liu et al., 2010). In C. elegans, frg1 protein 
localized both in nuclei and in the dense bodies that are homologous to vertebrate Z-disk. 
Interestingly frg1 overexpression in this invertebrate model disrupts the body-wall 
musculature and the muscular organization (Liu et al., 2010). In Xenopus both knock down 
and overexpression of frg1 resulted in defective growth and morphogenesis of the myotome 
indicating that precise levels of frg1 must be maintained for normal muscle morphology 
(Hanel et al., 2009). Together these results strongly suggest an evolutionary conserved 
function of FRG1 in muscular development. Additional evidences support the role of FRG1 
in muscle cell biology. FRG1 expression increases during myogenic differentiation. Its 
activation is paralleled by chromatin remodeling at the FRG1 promoter with loss of the 
polycomb repressor complex and replacement of the H3K27 trimethylation (H3K27me3) 
repression marker with the H3K4 trimethylation (H3K4me3) activation marker (Bodega et 
al., 2009). Interestingly the physical interaction between FRG1 promoter and D4Z4 array has 
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been shown (Petrov et al., 2008). In this context replacement of H3K27me3 by H3K4me3 
during myoblasts differentiation might indicate that chromatin structure undergoes 
dynamic changes during myogenic differentiation that lead to the loosening of the 
FRG1/4q-D4Z4 array loop in myotubes. Consistently, FRG1 over-expression was detected in 
the early stages of differentiation in FSHD myoblasts in comparison with control myoblasts 
(Bodega et al., 2009).  
FRG1 molecular function has not been elucidated yet. Several observations suggest that it 
could be involved in RNA processing. FRG1 is a nuclear protein that localizes in Cajal 
bodies, in nucleoli and in nuclear speckles, sites where RNA processing takes place (van 
Koningsbruggen et al., 2004). Its interaction with RNA has been demonstrated in vitro and in 
vivo (Sun et al., 2011). Proteomic studies found FRG1 as a component of purified 
spliceosomes (Rappsilber et al., 2002; Bessonov et al., 2010). Moreover in muscle of FRG1 
over-expressing transgenic mice, specific pre-mRNAs undergo aberrant alternative splicing 
(Gabellini et al., 2006). Studies showed that FRG1 has nuclear and cytoplasmic localizations. 
Interestingly in human muscle sections, FRG1 localizes with Z-disc (Hanel et al., 2011) an 
element of muscle sarcomere. In a muscle cells ribosomes are available at sarcomere for local 
synthesis of contractile proteins providing a mechanism to quickly respond to changes in 
the extra-cellular environment. It would be interesting to test wheter FRG1 is involved in Z 
line targeting and/or translation of specific m-RNAs. Despite the interest in FRG1 as 
candidate for FSHD pathogenesis has diminished because expression studies failed to detect 
FRG1 consistently overexpressed in FSHD biopsies (Gabellini et al., 2002; Jiang et al., 2003; 
Winokur et al., 2003b; Dixit et al., 2007; Osborne et al., 2007; Arashiro et al., 2009), 
experimental evidences point at the critical role of FRG1 in muscle development and 
indicate the presence of negative regulatory mechanisms on its expression, which is released 
in a myogenic-specific manner. On this basis FRG1 remains a very suitable candidate gene 
for FSHD pathophysiology. 
6.3 Adenine Nucleotide Translocator (ANT1)  
The Adenine Nucleotide Translocator gene (ANT1) is located approximately 4 Mb 
centromeric to the tandem array and encodes a 298-amino acid protein. This protein is a 
member of integral membrane transport molecules family that are among the most 
abundant constituents of the inner mitochondria membrane (IMM), responsible for the 
transport of adenine nucleotides across the inner mitochondrial membrane, importing ADP 
for oxidative phosphorylation and exporting ATP to the cytosol (Klingenberg and Aquila, 
1982). There are three different ANT genes in humans, ANT1, ANT2, and ANT3. These genes 
share 88% amino acid sequence identity and are characterized by a distinct tissue specific 
expression patterns (Levy et al., 2000; Stepien et al., 1992). ANT1 is the predominant isoform 
expressed in the mitochondria of heart and skeletal muscle tissue. In addition to regulating 
adenine nucleotide pools, ANT1 functions as a component of the mitochondrial 
permeability transition pore (PTP), which is essential for the release of pro-apoptotic 
proteins during the activation of the intrinsic-apoptosis pathway (Bauer et al., 1999; Sharer 
et al., 2002).  ANT1 overexpression seems critical in inducing programmed cell death in 
different eukaryotic cell lines (Bauer et al., 1999). Although mice overexpressing ANT1 do 
not show evident dystrophic phenotype (Figure 6A) (Gabellini et al., 2006), an increased 
amount of ANT1 protein was detected in both unaffected and affected FSHD muscles in 
 
Neuromuscular Disorders 38
comparison to healthy controls (Laoudj-Chenivesse et al., 2005).  Even though both increase 
of oxidative stress and ANT1 overexpression are proposed to be early events in the 
development of FSHD, it remains unclear if these are sequential or parallel processes 
(Winokur et al., 2003a). 
7. Epigenetic and FSHD: Role of methylation and chromatine structure 
Several clinical features, such as penetrance variability, gender bias in severity, asymmetric 
muscle wasting, and discordance in monozygotic twins, suggest that FSHD development 
involves epigenetic factors that can influence gene expression through local modification of 
chromatin structure.  
7.1 DNA methylation  
C5 methylation of cytosine, the most common epigenetic modification of mammalian DNA 
is known to be involved in development, X-chromosome inactivation, imprinting, and gene 
silencing (Robertson and Wolffe, 2000). CpG methylation can affect occupancy of specific 
genomic regions since several transcription factors and chromatin-binding proteins, such as 
CTCF and Yin Yang 1 (YY1), are sensitive to it (Hark et al., 2000; Kim et al., 2003).  Each 
D4Z4 repeat unit harbors two classes of GC-rich sequences, namely the low copy-repeats 
hhspm3 and LSau. This type of repetitive DNA is predominantly found in heterochromatic 
regions of the genome (Hewitt et al., 1994). On this basis, it has been hypothesized that 
D4Z4 repeat reduction might induce changes in chromatin conformation leading to 
inappropriate expression of 4q35 genes. The first study of DNA methylation at the D4Z4 
repeat array did not show a change in this epigenetic marker in FSHD tissues. D4Z4 was 
found highly methylated in both normal and FSHD lymphoblasts, as well as in somatic 
tissues, including skeletal muscle. Nevertheless the study did not discriminate between the 
methylation status of the repeat array at chromosome 4 or chromosome 10 (Tsien et al., 
2001). A subsequent study, revealed a significant hypomethylation of three different CpG 
dinucleotides of the D4Z4-reduced allele in lymphoblasts and muscle biopsies from FSHD 
patients (van Overveld et al., 2003). Importantly, low methylation levels at D4Z4 were 
observed at both chromosome 4 and 10 in the so-called phenotypic FSHD patients. These 
patients are clinically indistinguishable from 4q-linked FSHD patients but do not carry any 
D4Z4-reduced (de Greef et al, 2009). However, methylation levels can vary substantially 
between individuals. Generally, patients with residual repeat sizes between 10 and 19 kb (1-
3 D4Z4 units) are severely affected and show very low DNA methylation levels, whereas 
FSHD patients with repeat sizes between 20 and 31 kb (4-6 D4Z4 units) show inter-
individual variation in both clinical severity and D4Z4 hypomethylation (van Overveld et 
al., 2005). In addition, non-penetrant carriers show the same D4Z4 hypomethylation as their 
affected relatives and strong D4Z4 hypomethylation is also reported in patients with 
immunodeficiency, centromeric instability and facial anomalies syndrome (ICF) without any 
myopatic symptoms (Xu et al., 1999; Kondo et al., 2000; van Overveld et al., 2003). Currently, 
the role of D4Z4 hypomethylation in FSHD pathogenesis remains elusive.  
7.2 Histone modification 
Chromatin conformation results from the interaction between DNA and histone proteins 
and the involvement of other chromosomal proteins. The basic structural unit of chromatin 
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is the nucleosome that consists of 146 bp of DNA wrapped around a protein octamer of core 
histone proteins (Kornberg et al., 1974; Finch et al., 1977). Histone proteins may be 
posttranslational modified, by acetylation, methylation, phosphorylation, ubiquitination, 
SUMOylation and ADP-ribosylation (Bernstein et al., 2007). Modified histones are likely to 
control the structure and/or function of the chromatin fiber, with different modifications 
yielding distinct functional consequences. Furthermore, recruitment of chromatin-
associating proteins may depend upon the recognition of a specific histone modification 
pattern (Strahl and Allis, 2000; Peterson and Laniel, 2004). Extracellular and intracellular 
stimuli may change these patterns of modification, making the chromatin itself an integrator 
of various signaling pathways, ultimately affecting basic cellular processes such as 
transcription or replication (Cheung et al., 2000; Nightingale et al., 2006). In vivo, chromatin 
exists as fibers with differing degrees of compaction. The morphologically distinct classes of 
chromatin within the nucleus of higher eukaryotes are heterochromatin, which is more 
compacted and generally transcriptionally inactive, and euchromatin, wich is less 
compacted and generally transcriptionally active (Frenster et al., 1963). Although D4Z4 unit 
harbors two classes of repetitive DNA, hhspm3 and LSau, both of which are found 
predominantly in heterochromatic domains of the genome, FSHD locus at 4qter does not 
share some of the common properties of heterochromatin. For instance it does not co-
localize with DAPI-intense loci or it does not replicate in late S-phase. A recent study on 
D4Z4 histone modification seems to indicate that the repeat array may be organized in 
distinct domains, some characterized by transcriptionally repressive heterochromatin and 
others by transcriptionally permissive euchromatin (Zeng et al., 2009). These results indicate 
that the D4Z4 locus might display a chromatin structure more similar to euchromatin and 
favor the hypothesis that this region might be more dynamic than expected. Interestingly 
loss of marks of unexpressed heterochromatin such as histone H3K9me3 was observed in 
both FSHD with or without D4Z4 contraction. This phenomenon seems to be strictly 
associated with FSHD phenotype; in fact it was not found in ICF syndrome, despite its 
apparent similarity to FSHD with regard to D4Z4 DNA hypomethylation, or in other types 
of muscular dystrophies tested (Zeng et al., 2009). H3K9 methylation at D4Z4 is specifically 
mediated by the histone methyltransferase SUV39H1 (Zeng et al., 2009), which interacts 
with MyoD to suppress MyoD-dependent muscle gene expression (Mal, 2006). Interestingly, 
the heterochromatin binding protein HP1, which mediates transcriptional silencing 
(Bannister et al., 2001; Bernard et al., 2001), and the sister chromatid cohesion complex, 
cohesin, bind to D4Z4 in an H3K9me3-dependent manner and their recruitment is seriously 
compromised in FSHD (Zeng et al., 2009). These data support the indirect mechanism 
(Figure 5 C) where loss of repeats generates structural and functional modification, possibly 
through epigenetic changes in the histone pattern, which in turn might have an effect on 
transcriptional regulation in cis and/or in trans.  It is reasonable to anticipate that future 
studies on the possible chromatin organization involving D4Z4 and its changes in FSHD 
may provide critical insight into the mechanism of FSHD pathogenesis. 
7.3 Long distance effect: A repressor complex binding D4Z4 
The alteration of 4q35 gene expression observed in FSHD affected muscle (Gabellini et al., 
2002) raised the question whether D4Z4 was directly involved in transcriptional control of 
4q35 genes. The analysis of the interaction between D4Z4 and nuclear proteins revealed the 
presence of a 27 bp binding site (DBE, D4Z4 Binding Element) able to recruit a multi-protein 
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complex in vitro and in vivo comprising of YY1, HMGB2 and nucleolin, termed D4Z4 
Recognition Complex (DRC) (Gabellini et al., 2002). The ubiquitous transcription factor Yin 
Yang 1 (YY1) is a recruiter of polycomb group proteins (PcG), which are responsible for 
chromatin remodelling and epigenetic silencing in many fundamental biological processes. 
YY1, exerts its effects on genes involved in normal biologic processes such as 
embryogenesis, differentiation, replication, and cellular proliferation. Its ability to initiate, 
activate, or repress transcription depends upon context (Gordon et al., 2006). Furthermore, 
the activity of YY1 is modulated by histone deacetylases and histone acetyltransferases (Yao 
et al., 2001). HMGB2 is a member of one of the three families of high mobility group (HMG) 
proteins (Bustin, 1999; Bianchi and Beltrame, 2000;Agresti and Bianchi, 2003). It has been 
proposed that HMGB2 might be involved in the organization and/or maintenance of 
heterochromatic regions through the SP100-mediated interaction with HP1 (Lehming et al., 
1998). The third component of the DRC, nucleolin, is an abundant nucleolar protein, which 
has been implicated in chromatin structure, ribosomal RNA (rRNA) transcription, rRNA 
maturation, ribosome assembly and nucleo-cytoplasmic transport. To address whether the 
level of the DRC components influenced transcription of 4q35 genes, antisense experiments 
to decrease intracellular levels of DRC components were performed. These experiments 
showed that depletion of YY1, HMGB2 or nucleolin results in overexpression of the 4q35 
gene FRG2, which is silent in normal cells and tissues (Gabellini et al., 2002). Accumulating 
evidences indicate that gene regulation can be affected by physical interaction between two 
distant chromosomal regions in cis and in trans in mammalian cells (Tolhuis et al., 2002; 
Horike et al., 2005; Spilianakis et al., 2005; Lomvardas et al., 2006). Thus the DRC might 
exerts is inhibitory activity either modifying the chromatin structure or acting directly on 
4q35 genes promoters through a physical interaction mediated by the formation of a 
cromatin loop (Gabellini et al., 2002; Pirozhkova et al., 2008). The physical interaction 
between D4Z4 and FRG1 has been demonstrated (Pirozhkova et al., 2008; Bodega et al., 
2009) in normal myoblast by Chromosome conformation capture (3C), which is a technique 
that identifies long distance intra- and inter-chromosomal interactions (Dekker et al., 2002). 
Interestingly chromatin seems to undergo remodeling during myogenic differentiation. It 
has been shown that in normal myoblasts, the FRG1 gene is repressed and its promoter 
physically interacts with the D4Z4 array; upon differentiation, FRG1 gene is expressed and 
the chromatin loop between FRG1 promoter and D4Z4 is relaxed (Bodega et al.2009). 
Consistent with the observed mis-regulation of FRG1, a small reduction in the D4Z4–FRG1 
promoter interaction was observed in FSHD myoblasts compared with controls (Bodega et 
al., 2009). Different findings obtained with 3C analysis described the formation of loops 
between other elements in the FSHD locus (DUX4c and the 4qA/B marker) and the FRG1 
promoter (Pirozhkova et al., 2008). These data indicate that the tridimensional structure of 
the FSHD locus is complex and composite, probably more than one sequence elements (for 
example, D4Z4, DUX4c,4qA/B) or more than one chromatin modification factor might be 
required to obtain a fine regulation of FRG1 gene expression during muscle differentiation 
(Petrov et al., 2006; Pirozhkova et al., 2008). 
7.4 Subnuclear localization of 4q35 
The nucleoplasm is a high defined and structured compartment and chromosomes occupy 
specific and distinct territories. These chromosome territories are related to gene density, 
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transcriptional activity, replication timing, and chromosome size (Sun HB et al., 2000; 
Tanabe et al., 2002). The nucleoplasm is separated from the cytoplasm by the nuclear 
envelope (NE), consisting of an inner (INM) and outer nuclear membrane (ONM), (Gerace et 
al., 1988 ). Chromosome 4qter is preferentially localized in the outer nuclear periphery 
(Masny et al., 2004; Tam et al., 2004) although mammalian telomeres, including 10qter, are 
usually dispersed in the inner part of the nucleus (Ludérus et al., 1996; Nagele et al., 2001; 
Amrichová et al., 2003; Weierich et al., 2003). Sequences proximal to D4Z4, and not the 
repeat array itself, seem to be required to localize the 4q telomere at the periphery (Masny et 
al., 2004). These sequences are not found at 10qter and this may explain the different nuclear 
localization of 10qter. Recently, Ottaviani et al. (2009) identified an 80-bp sequence inside 
the D4Z4 unit that can trigger perinuclear positioning of artificial telomeres in a CTCF- and 
lamin A–dependent manner. Furthermore in cells lacking the lamin A gene, chromosome 4 
telomeres are dispersed (Masny et al., 2004). In addition, lamin A is shown to be associated 
with D4Z4 in vivo by chromatin immunoprecipitation and the perinuclear localization of 
4qter is largely lost in fibroblasts lacking lamin A/C (Ottaviani et al., 2009). Although 
Fluoresece In Situ Hybridization (FISH) analyses showed no change in the chromosome 4 
localization, between FSHD and healthy subjects, the peripheral environment of the FSHD 
4q35 allele may be altered because of modification in chromatin structure at D4Z4. This 
nuclear lamina alteration might produce a change in the binding of specific proteins, 
thereby contribute to the aberrant 4q35 gene expression reported in FSHD (Masny et al., 
2004; Tam et al., 2004; Ottaviani et al., 2009). 
8. Conclusions 
D4Z4 repeat contraction in patients with FSHD was discovered almost 20 years ago, 
nevertheless the exact molecular mechanism causing the FSHD phenotype has still not been 
elucidated and the search for a unifying model that can explain all the clinical features that 
have been observed in time has been frustrated. No histological or biochemical markers are 
available to independently confirm a specific FSHD diagnosis that remains mainly clinical. 
The molecular test primarily used for FSHD diagnosis was based on the initial observation 
that 95% of FSHD patients carry a reduction of integral numbers of D4Z4 repeats at 4q35 
with full penetrance (Van Deutekom et al., 2003). However the wide use of this test revealed 
several exceptions to the original assumption. Through the years the threshold size of D4Z4 
alleles has been increased from the original 28 kb (6 D4Z4 repeats) (Wimenga et al., 1999b) 
to 35 kb (8 D4Z4 repeats) (Van Deutekom et al., 2003), with FSHD cases carrying D4Z4 
alleles of 38-41 kb (9-11 D4Z4 repeats) considered borderline alleles (Butz et al., 2003; Vitelli 
et al., 1999). A further analysis of genotype-phenotype correlation led in time to the 
identification of subjects carrying D4Z4 reduced alleles with no sign of muscle weakness in 
FSHD families (Ricci et al., 1999; Tonini et al., 2004) as well as in normal controls (Van 
Overveld et al., 2000; Weiffenbach et al., 1992). The genotype-phenotype correlation 
conducted more recently on a large scale using a standardized method of evaluation 
allowed to estimate that 1) 20% of FSHD patients carry full-length D4Z4 alleles, 2) over 25% 
of relatives carrying D4Z4 reduced alleles do not have FSHD, 3) 3% of healthy subjects from 
the general population carry D4Z4 reduced alleles 4) no specific 4q haplotype is uniquely 
associated with FSHD. Remarkably, these studies established as a general rule rather than 
an exception that detection of a D4Z4 reduced allele is not sufficient to predict FSHD 
(Scionti et al., 2012a; Scionti et al., 2012b). Over the years, the molecular etiology of FSHD 
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has remained enigmatic, and the literature is filled with claims of causes that fail to be 
confirmed by other groups. Indeed, this might be expected if the clinical manifestation of 
FSHD symptoms is not only dependent on the structure/haplotype of D4Z4 contractions.  
This does not exclude an important pathogenic role for DUX4 or other candidate factors, but 
do establish a complex mechanism beyond current understanding indicating that a 
profound re-thinking of the genetic disease mechanism and modes of inheritance of FSHD is 
required.  
In-depth examination of disease points to a more complex genetic etiology in which D4Z4 
reduction might play a significant role only in association with other determinants, 
including genetic, epigenetic and environmental factors. Indeed, it is possible that in the 
heterozygous state a D4Z4 reduction might produce a predisposing condition that requires 
other epigenetic mechanisms or mutations in additional genes, both in cis and in trans, to 
cause overt myopathy. Finally it is also plausible that drugs or toxic agents might contribute 
to the disease onset and clinical variability. It is likely that, all mechanisms described above 
may contribute to the diverse phenotypic expression observed in carrier of D4Z4 reduced 
alleles. One of the major challenges for clinicians and researchers involved in FSHD studies 
will be to establish the weight that each single factor has in FSHD development. Particular 
attention should be paid to the relevance of epigenetics in the pathogenesis of FSHD. At the 
4q subtelomere chromatin is normally tightly packed, probably as facultative 
heterochromatin. However this region can be highly dynamic as demonstrated by the fact 
that in patients with FSHD, this chromatin structure becomes more open. As a consequence, 
regulation of candidate genes can be influenced by proteins that may bind to or be released 
from D4Z4. One of the major goals for future FSHD research will be to integrate these 
disease mechanisms into a single model that can be used to explain the clinical data and to 
improve the molecular diagnosis; both steps are essential to develop effective therapeutic 
strategies. 
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